Disease/Infection News

RSS

R&D of HIV treatments at crossroads

IP Overview HIV Therapy 2009” ( www.frinnov.fr/en/ip-overview/sciences-de-la-vie/hiv-therapy-2.html ) establishes a panorama of the patents claiming “HIV and AIDS treatments” and analyses the key and emerging thematic and the strategic positions of the actors involved in this sector. In order to fully analyze this field, the information coming from 6800 published patents and patent applications was aggregated.

4 Nov 2009

Colorful fruits and vegetables help boost immunity system

Hoping to keep the flu at bay? A strong immune system helps. Enjoying the bounty of colorful fruits and vegetables available right now can be an important step toward supporting your family's immune system this cold/flu season.

4 Nov 2009

Specimen Collection Kit to help medical personnel combat H1N1 and RSV

As the outbreak of H1N1 (Swine Flu) intensifies, there is a growing need for greater speed and accuracy in collecting specimens from patients for testing to determine with what they've been infected.

4 Nov 2009

News outlets examine first World Pneumonia Day

To mark the first World Pneumonia Day, Inter Press Service examines how vaccines and other strategies can be used to combat the disease, which kills more children under age 5 each year "than measles, malaria, and AIDS combined, according to the Global Coalition against Child Pneumonia."

4 Nov 2009

Malaria Conference addresses RTS,S vaccine, tools, treatment

On Tuesday at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, scientists and global health experts focused on malaria eradication, Agence France-Presse reports. "Key among the strategies ... is the development of an effective anti-malaria vaccine, a project scientists have been researching since the late 80s. ... RTS,S is the most clinically advanced malaria vaccine so far, according to the Malaria Vaccine Initiative," the news service writes (11/3).

3 Nov 2009

GlaxoSmithKline, Pfizer formally launch company to develop new HIV treatments

Pharmaceutical companies GlaxoSmithKline (GSK) and Pfizer on Tuesday formally launched ViiV Healthcare, a company focused on the development of new HIV treatments, Dow Jones Newswires/SmartMoney.com reports (11/3).

3 Nov 2009

Health affairs issue focuses on HIV/AIDS, NTDs

By 2031 developing countries could need an estimated $35 billion to fight HIV/AIDS - three times the amount currently spent, according to a Health Affairs study published Tuesday, the New York Times reports.

3 Nov 2009

Also in Global Health News: Breast cancer in developing world; Burkina Faso ITN distribution; diarrhea in people over age five; Gates Q&A

"International cancer specialists meet this week to plan an assault on a troubling increase of breast cancer in developing countries, where nearly two-thirds of women aren't diagnosed until it has spread through their bodies," the Associated Press reports. Researchers will also look at "some worrisome data" that suggests breast cancer affects "women, on average, about 10 years" earlier in developing countries than it does in the U.S. (Neergaard, 11/3).

3 Nov 2009

Vaccinating mothers against influeza during pregnancy prevents hospitalization in their infants

Infants born to women who received influenza vaccine during pregnancy were hospitalized at a lower rate than infants born to unvaccinated mothers, according to preliminary results of an ongoing study by researchers at Yale School of Medicine. The team presented the study October 29 at the 47th annual meeting of the Infectious Diseases Society of America in Philadelphia.

3 Nov 2009

Raycop's anti-bacterial vacuum cleaning system with UVC technology kills the H1N1 virus

Raycop, the first handheld anti-bacterial vacuum cleaning system and part of the Earlex® brands, offers a proven way to fight the H1N1 virus in the home with its UVC technology. The vac's effects against the virus have been independently tested by a leading international laboratory in August.

3 Nov 2009

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. A study led by Dr. Christian A Pineau, Co-Director of the Lupus and Vasculitis clinic at the MUHC, has clearly linked skin damage and rashes to smoking in people with systemic lupus erythematosus (SLE). The study was published in a recent issue of the Journal of Rheumatology.

3 Nov 2009

Schering-Plough to donate $200,000 and vaccine for rabies-control projects in India

Schering-Plough Corporation today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs. The company will donate $200,000 and rabies vaccine from Intervet/Schering-Plough as well as share expertise with partners to support successful implementation of the projects in ten villages surrounding Bangalore and Pune, India.

3 Nov 2009

Challenges in global health: rising to meet them could save millions of lives, say experts

Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs. The articles, by leading global health experts from around the world, show that although these challenges differ dramatically, rising to meet them could save millions of lives.

3 Nov 2009

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.

3 Nov 2009

Macomb County Health Department announces H1N1 influenza clinic

Another large community H1N1 influenza clinic has been scheduled by the Macomb County Health Department, the department announced today. It will be held at Freedom Hill County Park in Sterling Heights this Saturday, Nov. 7, from 9 a.m. to 3 p.m. Freedom Hill is located at 14900 Metropolitan Parkway.

3 Nov 2009

Tamiflu in short supply, pharmacists compound doses for children suffering from the H1N1 flu virus

Community pharmacists have stepped up to meet the shortage of Tamiflu by compounding doses for children suffering from the H1N1 flu virus, but they are struggling with supply problems and insurance plans, according to the National Community Pharmacists Association.

3 Nov 2009

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira and Remicade, which accounted for more than three-quarters of the market in 2008, will continue to grow through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

3 Nov 2009

Efficacy trial of the world's most clinically advanced malaria vaccine candidate underway

A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference.

3 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

FDA: Guidance document on diagnostic tests for the 2009 H1N1 influenza virus

The U.S. Food and Drug Administration today published a guidance document that should help manufacturers develop diagnostic tests for the 2009 H1N1 influenza virus. Although there are not any FDA-approved or cleared tests that diagnose this specific infection, during this pandemic, manufacturers can submit a request to the FDA for an Emergency Use Authorization (EUA).

3 Nov 2009

Disease/Infection News

R&D of HIV treatments at crossroads

Colorful fruits and vegetables help boost immunity system

Specimen Collection Kit to help medical personnel combat H1N1 and RSV

News outlets examine first World Pneumonia Day

Malaria Conference addresses RTS,S vaccine, tools, treatment

GlaxoSmithKline, Pfizer formally launch company to develop new HIV treatments

Health affairs issue focuses on HIV/AIDS, NTDs

Also in Global Health News: Breast cancer in developing world; Burkina Faso ITN distribution; diarrhea in people over age five; Gates Q&A

Vaccinating mothers against influeza during pregnancy prevents hospitalization in their infants

Raycop's anti-bacterial vacuum cleaning system with UVC technology kills the H1N1 virus

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

Schering-Plough to donate $200,000 and vaccine for rabies-control projects in India

Challenges in global health: rising to meet them could save millions of lives, say experts

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Macomb County Health Department announces H1N1 influenza clinic

Tamiflu in short supply, pharmacists compound doses for children suffering from the H1N1 flu virus

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

Efficacy trial of the world's most clinically advanced malaria vaccine candidate underway

Interim data from Schering-Plough's narlaprevir Phase IIa study

FDA: Guidance document on diagnostic tests for the 2009 H1N1 influenza virus

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News